‘Morphotek, Inc. - Product Pipeline Review - 2016’, provides an overview of the Morphotek, Inc.’s pharmaceutical research and development focus.

PUNE, INDIA, April 14, 2016 /EINPresswire.com/ -- The report “Morphotek, Inc. - Product Pipeline Review - 2016“ provides comprehensive information on the therapeutics under development by Morphotek, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Access a Report Copy @ https://www.wiseguyreports.com/reports/morphotek-inc-product-pipeline-review-2016 .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Morphotek, Inc.
- The report provides overview of Morphotek, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Morphotek, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Morphotek, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Purchase a 1-User License Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=393575 .

Reasons to buy

- Evaluate Morphotek, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Morphotek, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Morphotek, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Major Point in Table of Content

Morphotek, Inc. - Drug Profiles 14
amatuximab 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
farletuzumab 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ontuxizumab 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
KANAb-071 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MORAb-022 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MORAb-066 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody Conjugates for Oncology 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MORAb-047 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MORAb-048 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MORAb-050 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MORAb-075 29
Product Description 29
Mechanism of Action 29
R&D Progress 29

Inquire for more information @ https://www.wiseguyreports.com/enquiry/morphotek-inc-product-pipeline-review-2016 .

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
16468459349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.